Success Metrics

Active Trials
1(50%)

Phase Distribution

Ph early_phase_1
2
100%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Early Phase 1First-in-human
2(100.0%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 12 (100.0%)

Trials by Status

not_yet_recruiting150%
recruiting150%

Recent Activity

1 active trials
Showing 2 of 2
recruitingearly_phase_1

JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)

NCT06514768
not_yet_recruitingearly_phase_1

JY231(Internal Clinical Drug Code) Injection for the Treatment of Refractory Autoimmune Diseases

NCT06243159

Clinical Trials (2)

Showing 2 of 2 trials
NCT06514768Early Phase 1

JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting
NCT06243159Early Phase 1

JY231(Internal Clinical Drug Code) Injection for the Treatment of Refractory Autoimmune Diseases

Not Yet Recruiting

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2